Unfortunately, DMXAA displayed no benefit when used in combination with chemotherapy in a phase III clinical trial in patients with advanced NSCLC [92] and it was later shown that DMXAA is mouse-selective and does not activate human STING [57]. The gene discussed is STING1; the disease is non-small cell lung carcinoma.